Close Menu

NEW YORK – Myriad Genetics reported after the close of the market on Monday that its fiscal first quarter 2020 revenues declined by 8 percent year over year, mainly due to changes in CPT codes for hereditary cancer testing.

For the three months ended Sept. 30, revenues decreased to $186.3 million from $202.3 million in the year-ago quarter, well below analysts' average estimate of $202.1 million. Based on the Q1 performance, Myriad lowered its fiscal year 2020 revenue expectations.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

Sponsored by

This webinar will provide a behind-the-scenes look at the collaborative development of a novel multiplex assay to speed detection of mosquito-borne illness in the clinical setting.

Sponsored by

This webinar will explain how the Clinic for Special Children in Strasburg, Pennsylvania, has transformed its DNA workflows to improve the diagnosis and treatment of genetic illnesses that are prevalent in the pediatric population of its community.

Sponsored by

Since the publication of the “The Digital MIQE Guidelines: Minimum Information for Publication of Quantitative Digital PCR Experiments” (dMIQE) in 2013, there has been a large expansion of the applications of dPCR such as single nucleotide variations (SNVs) and copy number variations (CNVs) measurements associated with disease diagnostics.